All In MedTech

Device Trial Radar · NCT05111301

Control-IQ Technology in Individuals With Type 2 Diabetes

Control-IQ Technology in Individuals With Type 2 Diabetes (2IQ)

Last checked: Nov 20, 2026Latest source record: Mar 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

30

Actual

Start

Nov 30, 2021

Primary completion

Aug 10, 2022

Study completion Aug 18, 2022

Sponsor

Lead sponsor
Tandem Diabetes Care, Inc.Public (TNDM)
Sponsor type
Industry
Collaborators
Jaeb Center for Health Research
First posted
Nov 8, 2021

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A prospective, multicenter study of 6 weeks of home use of Control-IQ technology in individuals with type 2 diabetes age 18 and older.

Conditions

  • Type 2 Diabetes Treated With Insulin

Interventions

  • Control-IQ technology 1.5Device

    All subjects wearing the t-slim X2 insulin pump with Control-IQ technology 1.5, and wearing the Dexcom G6 sensor. Outcomes will be analyzed overall and subgroup analysis will be performed by Group, and by baseline A1c level.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. CGM Time Below 54 mg/dLTime frame: 14 weeks
  2. CGM Time Above 180 mg/dLTime frame: 14 weeks

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic

    Rochester, Minnesota

  • Icahn School of Medicine at Mt. Sinai

    New York, New York

  • Texas Diabetes and Endocrinology

    Austin, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.